Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 5
2016 2
2017 2
2018 1
2019 7
2020 6
2021 7
2022 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Population Pharmacokinetics of CC-122.
Cheng Y, Chen J, Pourdehnad M, Zhou S, Li Y. Cheng Y, et al. Clin Pharmacol. 2021 Apr 28;13:61-71. doi: 10.2147/CPAA.S310604. eCollection 2021. Clin Pharmacol. 2021. PMID: 33958900 Free PMC article.
METHODS: Nonlinear mixed effects modeling was employed in developing a population pharmacokinetic model of CC-122 based on 298 patients from 3 clinical studies. RESULTS: The PK of CC-122 was adequately described with a two-compartment model with first- …
METHODS: Nonlinear mixed effects modeling was employed in developing a population pharmacokinetic model of CC-122 based on 298 …
CC-122 immunomodulatory effects in refractory patients with diffuse large B-cell lymphoma.
Cubillos-Zapata C, Cordoba R, Avendaño-Ortiz J, Arribas-Jiménez C, Hernández-Jiménez E, Toledano V, Villaescusa T, Moreno V, López-Collazo E. Cubillos-Zapata C, et al. Oncoimmunology. 2016 Sep 16;5(12):e1231290. doi: 10.1080/2162402X.2016.1231290. eCollection 2016. Oncoimmunology. 2016. PMID: 28255524 Free PMC article.
The chemical structure of CC-122 includes the glutarimide moiety that is known to modulate the immune response. ...Finally, the activation of T cells through co-stimulatory molecule (CD28) was detected as a delayed CC-122 effect. In this context, CC …
The chemical structure of CC-122 includes the glutarimide moiety that is known to modulate the immune response. ...Finally, th …
Deciphering the mechanisms of CC-122 resistance in DLBCL via a genome-wide CRISPR screen.
Mo Z, Wood S, Namiranian S, Mizukoshi R, Weng S, Jang IS, Fontanillo C, Baughman JM, Silva-Torres A, Slade M, Khater M, Wang K, Rolfe M, Lu G. Mo Z, et al. Blood Adv. 2021 Apr 13;5(7):2027-2039. doi: 10.1182/bloodadvances.2020003431. Blood Adv. 2021. PMID: 33847741 Free PMC article.
Mechanistically, CC-122 induces the degradation of IKZF1/3, leading to T-cell activation and robust cell-autonomous killing in DLBCL. We report a genome-wide CRISPR/Cas9 screening for CC-122 in a DLBCL cell line SU-DHL-4 with follow-up mechanistic char …
Mechanistically, CC-122 induces the degradation of IKZF1/3, leading to T-cell activation and robust cell-autonomous killing in …
Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.
Ribrag V, Chavez JC, Boccomini C, Kaplan J, Chandler JC, Santoro A, Corradini P, Flinn IW, Advani R, Cassier PA, Sangha R, Kenkre VP, Isufi I, Uttamsingh S, Hagner PR, Gandhi AK, Shen F, Michelliza S, Haeske H, Hege K, Pourdehnad M, Kuruvilla J. Ribrag V, et al. EJHaem. 2022 Jan 14;3(1):139-153. doi: 10.1002/jha2.375. eCollection 2022 Feb. EJHaem. 2022. PMID: 35846221 Free PMC article.
In the multicenter, phase Ib CC-122-DLBCL-001 study (NCT02031419), the dose-escalation portion explored combinations of CC-122, CC-223, and CC-292 administered as doublets or triplets with rituximab in patients with chemorefractory DLBCL. ...CC- …
In the multicenter, phase Ib CC-122-DLBCL-001 study (NCT02031419), the dose-escalation portion explored combinations of CC …
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.
Krönke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Man HW, Gandhi AK, Svinkina T, Schneider RK, McConkey M, Järås M, Griffiths E, Wetzler M, Bullinger L, Cathers BE, Carr SA, Chopra R, Ebert BL. Krönke J, et al. Nature. 2015 Jul 9;523(7559):183-188. doi: 10.1038/nature14610. Epub 2015 Jul 1. Nature. 2015. PMID: 26131937 Free PMC article.
We further demonstrate that minor side chain modifications in thalidomide and a novel analogue, CC-122, can modulate the spectrum of substrates targeted by CRL4(CRBN). ...
We further demonstrate that minor side chain modifications in thalidomide and a novel analogue, CC-122, can modulate the spect …
A Novel Drug, CC-122, Inhibits Tumor Growth in Hepatocellular Carcinoma through Downregulation of an Oncogenic TCF-4 Isoform.
Tomimaru Y, Aihara A, Wands JR, Aloman C, Kim M. Tomimaru Y, et al. Transl Oncol. 2019 Oct;12(10):1345-1356. doi: 10.1016/j.tranon.2019.07.002. Epub 2019 Jul 25. Transl Oncol. 2019. PMID: 31352197 Free PMC article.
LEN and CC-122 significantly reduced the expression levels of TCF-4 J and its target genes (SPP1, AXIN2, MMP7, ASPH, CD24, ANXA1, and CAMK2N1); however, CC-122 was more potent. In a xenograft tumor model with a HAK-1A-TCF-4 J derived stable cells, tumo …
LEN and CC-122 significantly reduced the expression levels of TCF-4 J and its target genes (SPP1, AXIN2, MMP7, ASPH, CD24, ANX …
CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.
Hagner PR, Man HW, Fontanillo C, Wang M, Couto S, Breider M, Bjorklund C, Havens CG, Lu G, Rychak E, Raymon H, Narla RK, Barnes L, Khambatta G, Chiu H, Kosek J, Kang J, Amantangelo MD, Waldman M, Lopez-Girona A, Cai T, Pourdehnad M, Trotter M, Daniel TO, Schafer PH, Klippel A, Thakurta A, Chopra R, Gandhi AK. Hagner PR, et al. Blood. 2015 Aug 6;126(6):779-89. doi: 10.1182/blood-2015-02-628669. Epub 2015 May 22. Blood. 2015. PMID: 26002965 Free PMC article. Clinical Trial.
In DLBCL cell lines, CC-122-induced degradation or short hairpin RNA-mediated knockdown of Aiolos and Ikaros correlates with increased transcription of interferon (IFN)-stimulated genes independent of IFN-alpha, -beta, and -gamma production and/or secretion and resu …
In DLBCL cell lines, CC-122-induced degradation or short hairpin RNA-mediated knockdown of Aiolos and Ikaros correlates with i …
Exposure-response analysis to assess the concentration-QTc relationship of CC-122.
Li Y, Carayannopoulos LN, Thomas M, Palmisano M, Zhou S. Li Y, et al. Clin Pharmacol. 2016 Sep 9;8:117-25. doi: 10.2147/CPAA.S111867. eCollection 2016. Clin Pharmacol. 2016. PMID: 27672344 Free PMC article.
CC-122 is being developed as an oncology treatment for hematologic malignancies and advanced solid tumors. ...To assess the potential concentration-QTc relationship in humans and to ascertain or exclude a small QT effect by CC-122, a plasma concentrati …
CC-122 is being developed as an oncology treatment for hematologic malignancies and advanced solid tumors. ...To assess the po …
Single-Dose Pharmacokinetics, Safety, and Tolerability of Avadomide (CC-122) in Subjects With Mild, Moderate, or Severe Renal Impairment.
Li Y, MacGorman K, Liu L, Chen J, Hoffmann M, Palmisano M, Zhou S. Li Y, et al. Clin Pharmacol Drug Dev. 2020 Oct;9(7):785-796. doi: 10.1002/cpdd.760. Epub 2019 Dec 31. Clin Pharmacol Drug Dev. 2020. PMID: 31891240 Clinical Trial.
Given that renal clearance is one of the major routes of elimination for CC-122 and its clearance/exposure could be affected by renal impairment, a total of 50 subjects with various degrees of renal function were enrolled in an open-label, single-dose study to evalu …
Given that renal clearance is one of the major routes of elimination for CC-122 and its clearance/exposure could be affected b …
Novel immunomodulatory drugs and neo-substrates.
Gao S, Wang S, Song Y. Gao S, et al. Biomark Res. 2020 Jan 9;8:2. doi: 10.1186/s40364-020-0182-y. eCollection 2020. Biomark Res. 2020. PMID: 31938543 Free PMC article. Review.
Recently, novel thalidomide analogs have been designed for better clinical efficacy, including CC-122, CC-220 and CC-885. Moreover, a number of neo-substrates of IMiDs have been discovered. ...
Recently, novel thalidomide analogs have been designed for better clinical efficacy, including CC-122, CC-220 and CC-885. More …
32 results